Search research articles
Contact Us
Filters
Showing results (11-20 of 68) with videos related to
Page
of 7
Sort By:
Investigational New Drugs
|
October 21, 2006
Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors
Luis H Camacho, Jon Olson, William P Tong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 25, 2012
The impact of non-drug-related toxicities on the estimation of the maximum tolerated dose in phase I trials
Alexia Iasonos, Mrinal Gounder, David R Spriggs, et al.
Plos One
|
September 22, 2017
Time to publication of oncology trials and why some trials are never published
Paul B Chapman, Nathan J Liu, Qin Zhou, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM
|
May 11, 2010
Novel monoclonal antibodies against the proximal (carboxy-terminal) portions of MUC16
Thapi Dharma Rao, Kay J Park, Peter Smith-Jones, et al.
Gynecologic Oncology
|
October 8, 2003
Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy
Mario M Leitao, Amanda Hummer, Don S Dizon, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
November 15, 2011
Identifying clinical improvement in consolidation single-arm phase 2 trials in patients with ovarian cancer in second or greater clinical remission
Alexia Iasonos, Paul Sabbatini, David R Spriggs, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 15, 2010
Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen
Alena A Chekmasova, Thapi D Rao, Yan Nikhamin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 2002
Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer
Don S Dizon, Martee L Hensley, Elizabeth A Poynor, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
December 24, 2011
Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma
Robert A Soslow, Guangming Han, Kay J Park, et al.
Journal of Ovarian Research
|
February 19, 2024
Structural basis for antibody recognition of the proximal MUC16 ectodomain
Kwangkook Lee, Kay Perry, Mengyao Xu, et al.
Page
of 7
Search research articles
Search
Showing results (11-20 of 68) with videos related to
Sort By:
Page
of 7
Investigational New Drugs
|
October 21, 2006
Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors
Luis H Camacho, Jon Olson, William P Tong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 25, 2012
The impact of non-drug-related toxicities on the estimation of the maximum tolerated dose in phase I trials
Alexia Iasonos, Mrinal Gounder, David R Spriggs, et al.
Plos One
|
September 22, 2017
Time to publication of oncology trials and why some trials are never published
Paul B Chapman, Nathan J Liu, Qin Zhou, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM
|
May 11, 2010
Novel monoclonal antibodies against the proximal (carboxy-terminal) portions of MUC16
Thapi Dharma Rao, Kay J Park, Peter Smith-Jones, et al.
Gynecologic Oncology
|
October 8, 2003
Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy
Mario M Leitao, Amanda Hummer, Don S Dizon, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
November 15, 2011
Identifying clinical improvement in consolidation single-arm phase 2 trials in patients with ovarian cancer in second or greater clinical remission
Alexia Iasonos, Paul Sabbatini, David R Spriggs, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 15, 2010
Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen
Alena A Chekmasova, Thapi D Rao, Yan Nikhamin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 2002
Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer
Don S Dizon, Martee L Hensley, Elizabeth A Poynor, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
December 24, 2011
Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma
Robert A Soslow, Guangming Han, Kay J Park, et al.
Journal of Ovarian Research
|
February 19, 2024
Structural basis for antibody recognition of the proximal MUC16 ectodomain
Kwangkook Lee, Kay Perry, Mengyao Xu, et al.
Page
of 7